News
Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday.
Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
That pundit was HSBC's Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning. Image source: . Kumar ...
Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Novo Nordisk (NVO) stock draws mixed views from Wall Street analysts after the obesity drugmaker cut its 2025 outlook for the ...
2d
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its sales and profit estimates.
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
The Motley Fool on MSN2d
Why NovoCure Stock Is Cratering TodayThe company now expects full-year sales growth of 8% to 14%, down significantly from 13% to 21%. Its guidance for operating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback